Interleukin 35: Critical regulator of immunity and lymphocyte-mediated diseases.
Interleukin 35: Critical regulator of immunity and lymphocyte-mediated diseases.
复制标题
DOI：
10.1016/j.cytogfr.2015.07.013
复制
发表时间：
2015-10
影响因子：
13
通讯作者：
Wang R
中科院分区：
文献类型：
--
作者：
Egwuagu CE;Yu CR;Sun L;Wang R
细胞因子协调先天免疫系统和获得性免疫系统的活动，白介素12(IL-12)家族已成为感染性和自身免疫性疾病免疫的关键调节因子。一些成员(IL-12和IL-23)与慢性炎症性疾病的发病机制有关，而另一些成员(IL-27和IL-35)则减轻自身免疫性疾病。与主要由抗原提呈细胞产生的IL-12、IL-23和IL-27不同，IL-35主要由调节性B细胞(i35-Bregs)和T细胞(ITR35)分泌。IL-35可诱导淋巴细胞转化或扩增为调节性B细胞和T细胞，这一发现对自体调节性B细胞和T细胞在人类疾病中的治疗应用具有重要意义。尽管我们目前对IL-35或其亚单位(p35和Ebi3)的免疫生物学的了解还处于起步阶段，但我们在这篇综述中的目的是总结我们对这一神秘的细胞因子的了解及其潜在的临床应用，特别是在中枢神经系统自身免疫性疾病的治疗中。
Cytokines coordinate the activities of innate and adaptive immune systems and the Interleukin 12 (IL-12) family of cytokines has emerged as critical regulators of immunity in infectious and autoimmune diseases. While some members (IL-12 and IL-23) are associated with the pathogenesis of chronic inflammatory diseases, others (IL-27 and IL-35) mitigate autoimmune diseases. Unlike IL-12, IL-23 and IL-27 that are produced mainly by antigen presenting cells, IL-35 is predominantly secreted by regulatory B (i35-Bregs) and T (iTR35) cells. The discovery that IL-35 can induce the conversion or expansion of lymphocytes to regulatory B and T cells has considerable implications for therapeutic use of autologous regulatory B and T cells in human diseases. Although our current understanding of the immunebiology of IL-35 or its subunits (p35 and Ebi3) is still rudimentary, our goal in this review is to summarize what we know about this enigmatic cytokine and its potential clinical use, particularly in the treatment of CNS autoimmune diseases.